JACOBIO PHARMACEUTICALS GROUP CO., LTD. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.69 HKD | +5.62% |
|
+16.55% | -53.31% |
| Apr. 25 | Jacobio Pharmaceuticals Plans Auditor Change | MT |
| Apr. 09 | Jacobio to Share Clinical Data of Anti-Tumor Drugs at US Convention | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
Jacobio Pharmaceuticals Group Co Ltd is a China-based investment holding company mainly engaged in the research and development of new drugs at the clinical stage. The Company is primarily responsible for the independent discovery and development of innovative tumor therapies. The Company's main drug development projects include JAB-3068 and JAB-3312 clinical stage allosteric SHP2 inhibitors. The Company mainly conducts business within the domestic market.
Calendar
2024-08-27
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
1.481
CNY
Average target price
3.954
CNY
Spread / Average Target
+167.03%
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -53.31% | 162M | |
| -2.26% | 103B | |
| +1.41% | 95.71B | |
| +0.73% | 22.02B | |
| -17.84% | 20.9B | |
| -9.19% | 17.85B | |
| -42.83% | 16.21B | |
| -17.63% | 15.52B | |
| +4.55% | 13.86B | |
| +32.11% | 12.04B |
- Stock Market
- Equities
- 1167 Stock
- News Jacobio Pharmaceuticals Group Co., Ltd.
- Jacobio Pharmaceuticals : Completes the Dosage of Two Patients in its SHP2 Study
